BEARINGPOINT
20.6.2022 10:49:12 CEST | Business Wire | Press release
Management and technology consultancy BearingPoint has acquired I Care, a consultancy firm specializing in sustainability strategy development and environmental transition. With the integration, BearingPoint expands its offerings in the area of sustainability consulting and accelerates growth in its key consulting markets.
Established in 2008, I Care has more than 80 employees in France and Brazil and offers consulting services to public organizations, NGOs, private companies and financial institutions to respond to the risks and opportunities of the environmental transition. I Care distinguished itself by developing innovative methods and tools to quantify the performance of actors in the area of low-carbon transition and biodiversity footprint. By hybridizing scientific and strategy consulting skills, I Care has positioned itself as a key player in helping organizations define and implement environmental strategies.
“I Care’s capabilities and service offerings match perfectly with the needs of our clients in Europe. Moreover, we share the same culture of an entrepreneurial, holistic mindset and are trusted advisors for our clients. Together we look forward to becoming the key player in sustainable and environmental transformation consulting in France and entering selected markets internationally,” says Axelle Paquer, Regional Leader for France, Belgium, Luxemburg and Africa at BearingPoint.
BearingPoint , with more than 1,000 employees in France and 4,300 in Europe, has had a dedicated practice in sustainable development since 2010. This includes support for companies and public organizations in strategy, digital responsibility and the calculation of carbon emissions with its emissions calculator solution. BearingPoint is thus strengthening its ability to support clients in all aspects of their sustainable development strategies.
“I Care has a strong reputation for helping clients drive sustainability strategies and environmental transformation. Its proven practice and methodology combined with our transformation and digitalization capabilities will allow us to develop compelling new value propositions for our existing client portfolio in Europe, the US and China,” says Kiumars Hamidian, Managing Partner BearingPoint.
“Joining BearingPoint will enable I Care to accelerate our growth plans within a range of industry sectors in France and open the doors into more markets internationally. We are keen to leverage BearingPoint’s wider capabilities, notably in services such as emissions calculation and digital transformation, to benefit our existing client base. Becoming part of a leading international consulting organization opens up an opportunity to further increase our impact on society. ” says Guillaume Neveux, founder and CEO at I Care.
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: Consulting, Products, and Capital. Consulting covers the advisory business with a clear focus on selected business areas. Products provides IP-driven digital assets and managed services for business-critical processes. Capital delivers M&A and transaction services.
BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
For more information about BearingPoint, please visit:
Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint
About I Care
I Care is a leading consulting company in the environmental field. Since 2008, I Care assists companies, financial institutions, and public organizations in their transition towards a low environmental impact society.
Combining expertise in strategy, finance, project management, and technical skills, its ambition is to provide clients with global solutions to their environmental challenges with the objective of moving to a sustainable economy. Thanks to its multidisciplinary approach between environmental expertises, consulting, research, the private, and public sectors, I Care has a wide range of skills providing a comprehensive response to the diverse needs in the field of sustainable development.
For more information about I Care, please visit:
Homepage: https://www.i-care-consult.com/
LinkedIn: https://www.linkedin.com/company/i-care-environnement/
Twitter: https://twitter.com/I_Care_Consult
View source version on businesswire.com: https://www.businesswire.com/news/home/20220620005150/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom